- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05781048
A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
March 21, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
An Open-label, Multi-center Phase I Study of Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in patients with advanced solid tumors.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
90
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaoyu Zhu
- Phone Number: 0518-82342973
- Email: xiaoyu.zhu@hengrui.com
Study Contact Backup
- Name: Yueling Wang
- Phone Number: 021-60453139
- Email: yueling.wang@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be willing to participate in the study, sign the informed consent form, have good compliance, and cooperate with follow-up visits.
- Aged 18-80 years, male or female
- Patients with advanced malignant tumors confirmed pathologically;
- Failure of adequate standard treatment, or no effective standard treatment;
- Patients must have at least 1 extracranial measurable target lesion per RECIST v1.1 ;
- The expected survival period is more than 12 weeks;
- The Eastern Cooperative Oncology Group (ECOG) physical fitness score is 0 - 1;
- Have sufficient bone marrow and organ function (have not received blood transfusion or hematopoietic stimulating factor treatment within 14 days);
- Female subjects of childbearing age must undergo a serum pregnancy test within 3 days before starting the study medication, and the result is negative, and are willing to use a medically approved high-efficiency contraception during the study period and within 6 months after the last administration of the study drug Measures: For male subjects whose partners are females of childbearing age, they should be surgically sterilized, or agree to use effective methods of contraception during the study period and within 3 months after the last study administration;
Exclusion Criteria:
- Subjects with a history of malignant tumors, except patients with cutaneous basal cell carcinoma, superficial bladder cancer, cutaneous squamous cell carcinoma or cervical carcinoma in situ who have undergone possible curative treatment and did not have disease recurrence within 3 years since starting the treatment;
- Subjects had cancerous meningitis or untreated central nervous system metastases
- Subjects experienced intestinal obstruction and gastrointestinal perforation within 3 months prior to initial medication
- There is third-space effusion that cannot be controlled by drainage and other methods (such as massive ascites, pleural effusion, pericardial effusion);
- Subjects had clinical cardiac symptoms or disease that was not well controlled within 6 months prior to initial medication
- Subjects had or currently had idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia , drug pneumonia, or CT during screening showed active pneumonia;
- Arteriovenous thrombosis occurred within 6 months prior to the first dose
- Severe infection occurred within 4 weeks prior to initial administration
- During the screening period/before the first administration, fever of unknown origin> 38.5°C
- Known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS)
- Subjects had active hepatitis;
- Subjects received live attenuated vaccine within 4 weeks or planned for the study period prior to initial administration;
- Subjects were scheduled to receive other systemic antitumor therapies during the study period;
- Participated in other clinical studies within 4 weeks before starting the study drug treatment;
- Subjects were unable to swallow pills or capsules normally, or had gastrointestinal abnormalities that the researchers determined might affect drug absorption;
- Other factors as judged by the investigator that may lead to the termination of the study, such as other serious diseases, serious laboratory test abnormalities, or family or social factors that could affect the safety of the subject, or the collection of study data and samples.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HRS-6209
|
HRS-6209
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety endpoints: Number of subjects with adverse events and the severity of adverse events
Time Frame: every 4 weeks after treatment initiation,up to approximately 2 years.
|
every 4 weeks after treatment initiation,up to approximately 2 years.
|
DLT(Dose-limiting toxicity)
Time Frame: during the first 30-day cycle of SHR-6209 treatment
|
during the first 30-day cycle of SHR-6209 treatment
|
MTD(Maximum tolerated dose)
Time Frame: 4 weeks after treatment initiation
|
4 weeks after treatment initiation
|
RP2D(Recommended Phase II Dose)
Time Frame: 4 weeks after treatment initiation
|
4 weeks after treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR(Objective response rate (ORR) - RECIST 1.1
Time Frame: Up to approximately 6 months
|
ORR is defined as the proportion of subjects who have achieved complete response (CR) or partial response (PR) according to RECIST 1.1)
|
Up to approximately 6 months
|
DoR(Duration of Response (DoR)Duration of Response (DoR) per RECIST 1.1)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
DCR(Disease control rate(DCR)-RECIST 1.1
Time Frame: Up to approximately 2 years
|
DCR is defined as the proportion of subjects who have achieved Stable disease(SD)、complete response (CR) or partial response (PR) according to RECIST 1.1)
|
Up to approximately 2 years
|
PFS-Progression-free survival(PFS) PFS per RECIST 1.1
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 1, 2023
Primary Completion (Anticipated)
December 30, 2026
Study Completion (Anticipated)
December 30, 2026
Study Registration Dates
First Submitted
February 23, 2023
First Submitted That Met QC Criteria
March 21, 2023
First Posted (Actual)
March 23, 2023
Study Record Updates
Last Update Posted (Actual)
March 23, 2023
Last Update Submitted That Met QC Criteria
March 21, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-6209-I-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
Clinical Trials on HRS-6209
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruitingAdvanced Malignant Tumour
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Grupo Español de Rehabilitación MultimodalUnknownArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSpain
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Prostate CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced KRAS G12D Mutant Solid TumorsChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Guangdong Hengrui Pharmaceutical Co., LtdRecruitingChronic Obstructive Pulmonary DiseaseChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRecurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaChina